PMID- 31089385
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1735-0328 (Print)
IS  - 1726-6890 (Electronic)
IS  - 1726-6882 (Linking)
VI  - 18
IP  - 1
DP  - 2019 Winter
TI  - Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association 
      among Pediatrics.
PG  - 506-522
AB  - Severe cutaneous adverse drug reaction (SCAR) is considered to be a 
      multifactorial drug side effect. This study was designed to investigate the 
      epidemiology and human leukocyte antigen (HLA)-A and -B gene polymorphisms in 
      pediatric patients with SCAR admitted in tertiary referral center, southwestern 
      of Iran from 2013 to 2017. Demographic data, past allergy and autoimmune history, 
      clinical presentations, drugs confirmed to be the cause of SCAR as well as its 
      therapy were reviewed for each patient. HLA-A and -B allele frequencies were 
      determined in 40 of the patients using polymerase chain reaction based on 
      sequence specific primers (PCR-SSP) and compared with 40 healthy individuals as 
      control group. Sixty-one patients with mean age of 6 years old and boy to girl 
      ratio was 1.2/1 in this study. The most common type of SCAR in our patients was 
      Steven Johnson Syndrome (SJS)/Toxic Epidermal Necrosis (TEN) mainly caused by 
      beta-lactam antibiotics. Carbamazepine was the second cause of drug-induced SCAR. 
      Moreover, HLA-A*02:01 and A*51:01 were related to the increased risk of SCAR 
      while A*11:01 seemed to be protective against SCAR. HLA-A*02:01, HLA-A*24:02, and 
      HLA-B*51:01 showed associations to the increased risk of SJS. Based on our 
      results, beta-lactam antibiotics and antiepileptic drugs are the most common 
      causes of severe adverse drug reaction in southwestern Iranian pediatric 
      patients. Moreover, some HLA-A alleles can influence risk of SCAR.
FAU - Esmaeilzadeh, Hossein
AU  - Esmaeilzadeh H
AD  - Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
AD  - Department of Allergy and Clinical Immunology, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Farjadian, Shirin
AU  - Farjadian S
AD  - Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Alyasin, Soheila
AU  - Alyasin S
AD  - Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
AD  - Department of Allergy and Clinical Immunology, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Nemati, Hamid
AU  - Nemati H
AD  - Shiraz Neuroscience Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Nabavizadeh, Hesamodin
AU  - Nabavizadeh H
AD  - Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
AD  - Department of Allergy and Clinical Immunology, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Esmaeilzadeh, Elmira
AU  - Esmaeilzadeh E
AD  - Department of Internal Medicine, Division of Rheumatology, Shiraz University of 
      Medical Sciences, Shiraz, Iran.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Iran J Pharm Res
JT  - Iranian journal of pharmaceutical research : IJPR
JID - 101208407
PMC - PMC6487414
OTO - NOTNLM
OT  - AGEP
OT  - DHR
OT  - DRESS
OT  - HLA
OT  - SCAR
OT  - STS/TEN
EDAT- 2019/05/16 06:00
MHDA- 2019/05/16 06:01
PMCR- 2019/01/01
CRDT- 2019/05/16 06:00
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2019/05/16 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - ijpr-18-506 [pii]
PST - ppublish
SO  - Iran J Pharm Res. 2019 Winter;18(1):506-522.